MicroPort CardioFlow Medtech Corp. (HK:2160)
:2160
Top Page
MicroPort CardioFlow Medtech Corp.
(2160)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$0.76
▼(-39.04% Downside)
Action:ReiteratedDate:01/31/26
The score is primarily weighed down by ongoing losses and weak cash generation, alongside clear bearish technicals (price below major moving averages and negative MACD). A strong equity base and low leverage provide some financial stability, but valuation is difficult to justify given the very high P/E and no dividend support.
Positive Factors
Balance-sheet strength
An 81.74% equity ratio and minimal leverage (0.04 D/E) provide durable financial resilience. Low debt reduces default and interest risks, giving management flexibility to fund product development and commercialization from internal or equity sources during multi‑year adoption cycles.
Negative Factors
Persistent unprofitability
Sustained negative EBIT and net losses weaken the firm's ability to generate returns and reinvest internally. Extended unprofitability risks continual equity dilution or external funding needs, constraining strategic initiatives and reducing resilience to setbacks during multi‑year commercialization efforts.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
An 81.74% equity ratio and minimal leverage (0.04 D/E) provide durable financial resilience. Low debt reduces default and interest risks, giving management flexibility to fund product development and commercialization from internal or equity sources during multi‑year adoption cycles.
Read all positive factors
MicroPort CardioFlow Medtech Corp. (2160) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.73B
Dividend YieldN/A
Average Volume (3M)8.07M
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue Growth-4.38%
EPS GrowthN/A
CountryHK
Employees430
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.68
Price to Sales (P/S)4.13
P/FCF Ratio-5.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)HK$2.15B
MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model
Company Description
MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve Syst...
How the Company Makes Money
MicroPort CardioFlow Medtech Corp. generates revenue through the sale of its medical devices and technologies to hospitals, clinics, and healthcare providers. The company’s key revenue streams include direct sales of cardiovascular devices, such a...
MicroPort CardioFlow Medtech Corp. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 367.53M | 361.56M | 336.21M | 251.03M | 200.81M | 103.93M |
| Gross Profit | 253.91M | 251.21M | 229.93M | 162.13M | 118.70M | 45.38M |
| EBITDA | -87.81M | -113.32M | -386.05M | -347.91M | -173.99M | -227.43M |
| Net Income | 4.85M | -49.45M | -471.53M | -454.39M | -183.26M | -398.09M |
Balance Sheet | ||||||
| Total Assets | 2.67B | 2.68B | 2.58B | 3.00B | 3.36B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 1.32B | 1.36B | 1.07B | 2.08B | 2.42B | 612.47M |
| Total Debt | 279.62M | 76.86M | 70.48M | 95.47M | 125.64M | 15.83M |
| Total Liabilities | 450.55M | 454.07M | 242.25M | 247.55M | 265.52M | 1.46B |
| Stockholders Equity | 2.18B | 2.19B | 2.33B | 2.75B | 3.10B | -345.18M |
Cash Flow | ||||||
| Free Cash Flow | -179.62M | -270.06M | -237.50M | -231.60M | -269.94M | -167.97M |
| Operating Cash Flow | -26.82M | -111.67M | -206.99M | -182.53M | -161.50M | -109.75M |
| Investing Cash Flow | -668.17M | -798.50M | -596.06M | -179.78M | -437.48M | -56.42M |
| Financing Cash Flow | -2.75M | -56.31M | -25.61M | -136.42M | 2.23B | 676.42M |
MicroPort CardioFlow Medtech Corp. Technical Analysis
Negative
1.25
Price Trends
3.86
Negative
4.81
Negative
5.55
Negative
Market Momentum
-0.26
Positive
27.15
Positive
23.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2160, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 3.31, below the 50-day MA of 3.86, and below the 200-day MA of 5.55, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 27.15 is Positive, neither overbought nor oversold. The STOCH value of 23.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2160.
MicroPort CardioFlow Medtech Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$7.11B | 17.31 | 11.91% | 1.26% | 25.18% | 55.79% | |
69 Neutral | HK$8.15B | 19.30 | 9.39% | 1.88% | 14.56% | 61.60% | |
53 Neutral | HK$961.41M | -1.91 | -30.05% | ― | -8.56% | -14.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.13B | -18.13 | -11.27% | ― | 29.25% | 9.02% | |
43 Neutral | HK$3.73B | -218.71 | 0.22% | ― | -4.38% | ― | |
40 Underperform | HK$235.29M | 10.43 | -34.76% | ― | 6.10% | -115.12% |
* Healthcare Sector Average
HK:2160
MicroPort CardioFlow Medtech Corp.
2.93
-1.62
-35.60%
HK:9996
Peijia Medical Ltd.
6.16
1.06
20.78%
HK:1789
AK Medical Holdings Ltd.
6.34
0.33
5.49%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
13.83
3.92
39.56%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.10
0.01
12.22%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.18
-0.06
-2.68%
MicroPort CardioFlow Medtech Corp. Corporate Events
MicroPort CardioFlow Revises Timetable for Planned Share Consolidation
Jan 30, 2026
MicroPort CardioFlow Medtech Corporation has revised the expected timetable for its proposed share consolidation, citing additional time needed for logistical arrangements related to trading operations. The new schedule confirms key dates for shar...
MicroPort CardioFlow Proposes 5-for-1 Share Consolidation in Hong Kong
Jan 26, 2026
MicroPort CardioFlow Medtech Corp. has proposed a share consolidation that will combine every five existing shares into one consolidated share, raising the par value per share while keeping the company’s total authorised share capital unchan...
MicroPort CardioFlow Calls EGM to Approve 5-for-1 Share Consolidation
Jan 26, 2026
MicroPort CardioFlow Medtech Corporation has called an extraordinary general meeting (EGM) for 11 February 2026 in Shanghai, where shareholders will vote on a proposed share consolidation at a ratio of five existing shares into one consolidated sh...
MicroPort CardioFlow Sets February EGM to Approve 5-for-1 Share Consolidation
Jan 22, 2026
MicroPort CardioFlow Medtech Corporation has called an extraordinary general meeting for 11 February 2026 to seek shareholder approval for a share consolidation, under which every five existing issued and unissued shares with a par value of US$0.0...
MicroPort CardioFlow Reports Strong One-Year AltaValve TMVR Data as Device Advances in Global Trials
Dec 30, 2025
MicroPort CardioFlow Medtech Corporation announced the formal release of one-year follow-up data from an early feasibility study of AltaValve, a transcatheter mitral valve replacement device independently developed by its associated company 4C Med...
MicroPort CardioFlow Accelerates Global TAVI Expansion with Strong 2025 Growth Outlook
Dec 30, 2025
MicroPort CardioFlow Medtech Corporation announced that its VitaFlow series TAVI systems have now been introduced in 35 countries and regions, with cumulative implantations nearing 1,300 cases. The company expects implantation volume in 2025 to ex...
MicroPort CardioFlow Completes Major Acquisition to Expand into Cardiac Rhythm Management
Dec 21, 2025
MicroPort CardioFlow Medtech Corporation has completed the acquisition of MicroPort Cardiac Rhythm Management Limited and its subsidiaries, which have now become indirect subsidiaries of the group. The deal, structured as a very substantial acquis...
MicroPort CardioFlow Medtech Corp. Announces Board Composition
Dec 15, 2025
MicroPort CardioFlow Medtech Corp. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the company’s leadership structure, which is crucial for i...
MicroPort CardioFlow Medtech Corp. Shareholders Approve Strategic Merger
Dec 15, 2025
MicroPort CardioFlow Medtech Corp. announced that its shareholders approved a merger agreement at an extraordinary general meeting held on December 15, 2025. The merger involves MicroPort CardioFlow CRM Limited and MicroPort Cardiac Rhythm Managem...
MicroPort CardioFlow Announces Board Changes and New Co-Chairman
Dec 15, 2025
MicroPort CardioFlow Medtech Corp. announced significant changes in its board of directors, with the resignation of Mr. Zhao Liang, Ms. Yan Luying, and Mr. Zhang Junjie, effective December 15, 2025. The company expressed gratitude for their contri...
MicroPort CardioFlow Medtech Corp. Restructures Board and Targets Heart Failure Market
Dec 15, 2025
MicroPort CardioFlow Medtech Corp. has announced significant changes in its board committees and the establishment of new strategic committees to enhance its market positioning. The company aims to leverage its technological capabilities and exper...
MicroPort CardioFlow Clarifies EGM Voting Deadline
Nov 25, 2025
MicroPort CardioFlow Medtech Corporation has issued a supplemental announcement to clarify the deadline for lodging share transfers to qualify for voting rights at the upcoming Extraordinary General Meeting (EGM). The corrected deadline is now set...
MicroPort CardioFlow Medtech Announces Merger Plans
Nov 24, 2025
MicroPort CardioFlow Medtech Corp. has announced an extraordinary general meeting to discuss a proposed merger with MicroPort Cardiac Rhythm Management Limited. The merger involves issuing new shares to the target company’s shareholders, whi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.